SEC Form 4 · accession 0001209191-19-016081
TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Daniell
Officer — Exec. VP, European Commercial
Period of report
Mar 3, 2019
Accepted (ET)
Mar 5, 2019 · 7:05 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818686
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Mar 3, 2019 | M | 2,098 | — | A | 2,098 | D | |
| Ordinary SharesF1,F3 | Mar 4, 2019 | S | 2,098 | $16.8844 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF2,F4,F1 | — | Mar 3, 2019 | M | 2,098 | D | — | — | Ordinary Shares | 2,098 | 4,199 | D |
Explanation of responses
- F1The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- F2Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.755 to $17.1316, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4Restricted share units were granted on March 3, 2017, with 2,098 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 2,101 vesting on March 3, 2021.